C
CRINETICS PHARMACEUTICALS INC
NASDAQ: CRNX (Crinetics Pharmaceuticals, Inc.)
Last update: 18 hours ago30.99
0.34 (1.11%)
| Previous Close | 30.65 |
| Open | 30.67 |
| Volume | 1,107,605 |
| Avg. Volume (3M) | 823,176 |
| Market Cap | 2,918,514,176 |
| Price / Sales | 1.99 |
| Price / Book | 2.49 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Operating Margin (TTM) | -30,860.11% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | -43.60% |
| Total Debt/Equity (MRQ) | 4.05% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -261.57 M |
| Levered Free Cash Flow (TTM) | -155.77 M |
| Return on Assets (TTM) | -20.13% |
| Return on Equity (TTM) | -30.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 5.0 |
| Insider Activity | -4.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.30 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 112.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 86.00 (JMP Securities, 177.51%) | Buy |
| Median | 83.50 (169.44%) | |
| Low | 81.00 (HC Wainwright & Co., 161.38%) | Buy |
| Average | 83.50 (169.44%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 28.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 11 Aug 2025 | 86.00 (177.51%) | Buy | 27.38 |
| HC Wainwright & Co. | 27 Jun 2025 | 81.00 (161.37%) | Buy | 29.96 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PIZZUTI DANA | - | 30.01 | -36,492 | -1,116,452 |
| Aggregate Net Quantity | -36,492 | |||
| Aggregate Net Value ($) | -1,116,452 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 30.01 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PIZZUTI DANA | Officer | 22 Aug 2025 | Automatic sell (-) | 30,000 | 30.92 | 927,600 |
| PIZZUTI DANA | Officer | 22 Aug 2025 | Option execute | 30,000 | - | - |
| PIZZUTI DANA | Officer | 20 Aug 2025 | Automatic sell (-) | 6,492 | 29.09 | 188,852 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |